{"entity":{"type":"insider","cik":"0001777653","url":"/insider/0001777653","json_url":"/insider/0001777653.json","name":"Versant Vantage I GP-GP, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":32,"n_filings":12,"first":"2019-10-07","last":"2025-09-23","span_basis":"filed_date"},"name_variants":[{"name":"Versant Vantage I GP-GP, LLC","source":"filing","n_filings":12,"first_seen":"2019-10-07","last_seen":"2025-09-23"}],"transactions":[{"id":5025160,"accession":"0001193125-25-213445","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-213445","line_url":"/filing/0001193125-25-213445","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2903403.0,"shares_display":"2,903,403","price_per_share":1.4014,"price_display":"1.40","price_state":"stated","total_value":4068828.9642,"total_display":"4,068,828.96","total_whole":"4,068,829","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-19","filed_date":"2025-09-23","scope":"insider","n_lines":2},{"id":4990228,"accession":"0001193125-25-207677","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-25-207677","line_url":"/filing/0001193125-25-207677","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":594902.0,"shares_display":"594,902","price_per_share":1.4418,"price_display":"1.44","price_state":"stated","total_value":857729.7036,"total_display":"857,729.70","total_whole":"857,730","shares_owned_after":2370533.0,"shares_owned_after_display":"2,370,533","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-18","filed_date":"2025-09-18","scope":"insider","n_lines":2},{"id":4990217,"accession":"0001193125-25-207677","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-207677","line_url":"/filing/0001193125-25-207677","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":589532.0,"shares_display":"589,532","price_per_share":1.4892,"price_display":"1.49","price_state":"stated","total_value":877931.0544,"total_display":"877,931.05","total_whole":"877,931","shares_owned_after":2736644.0,"shares_owned_after_display":"2,736,644","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-17","filed_date":"2025-09-18","scope":"insider","n_lines":2},{"id":4990207,"accession":"0001193125-25-207677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-207677","line_url":"/filing/0001193125-25-207677","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":1.5332,"price_display":"1.53","price_state":"stated","total_value":766600.0,"total_display":"766,600.00","total_whole":"766,600","shares_owned_after":3099450.0,"shares_owned_after_display":"3,099,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-16","filed_date":"2025-09-18","scope":"insider","n_lines":2},{"id":3112863,"accession":"0000950170-24-119051","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0000950170-24-119051","line_url":"/filing/0000950170-24-119051","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67905.0,"shares_display":"67,905","price_per_share":9.15692125027612,"price_display":"9.16","price_state":"stated","total_value":621800.7375,"total_display":"621,800.74","total_whole":"621,801","shares_owned_after":1589053.0,"shares_owned_after_display":"1,589,053","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-29","filed_date":"2024-10-30","scope":"insider","n_lines":2},{"id":3112856,"accession":"0000950170-24-119051","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000950170-24-119051","line_url":"/filing/0000950170-24-119051#line-11","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":89990.0,"shares_display":"89,990","price_per_share":9.6593,"price_display":"9.66","price_state":"stated","total_value":869240.407,"total_display":"869,240.41","total_whole":"869,240","shares_owned_after":2007948.0,"shares_owned_after_display":"2,007,948","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-28","filed_date":"2024-10-30","scope":"insider"},{"id":2083039,"accession":"0000950170-24-109112","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-109112","line_url":"/filing/0000950170-24-109112#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1132566.0,"shares_display":"1,132,566","price_per_share":6.5296,"price_display":"6.53","price_state":"stated","total_value":7395202.9536,"total_display":"7,395,202.95","total_whole":"7,395,203","shares_owned_after":5099336.0,"shares_owned_after_display":"5,099,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-20","filed_date":"2024-09-24","scope":"insider"},{"id":2897808,"accession":"0000950170-24-106532","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-106532","line_url":"/filing/0000950170-24-106532#line-3","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9269.0,"shares_display":"9,269","price_per_share":6.1603,"price_display":"6.16","price_state":"stated","total_value":57099.8207,"total_display":"57,099.82","total_whole":"57,100","shares_owned_after":6231902.0,"shares_owned_after_display":"6,231,902","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-13","scope":"insider"},{"id":2897804,"accession":"0000950170-24-106532","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-106532","line_url":"/filing/0000950170-24-106532#line-2","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16047.0,"shares_display":"16,047","price_per_share":6.0017,"price_display":"6.00","price_state":"stated","total_value":96309.2799,"total_display":"96,309.28","total_whole":"96,309","shares_owned_after":6241171.0,"shares_owned_after_display":"6,241,171","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-12","filed_date":"2024-09-13","scope":"insider"},{"id":2897797,"accession":"0000950170-24-106532","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-106532","line_url":"/filing/0000950170-24-106532#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":541897.0,"shares_display":"541,897","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":3251382.0,"total_display":"3,251,382.00","total_whole":"3,251,382","shares_owned_after":6257218.0,"shares_owned_after_display":"6,257,218","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-13","scope":"insider"},{"id":6803913,"accession":"0000899243-22-021350","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000899243-22-021350","line_url":"/filing/0000899243-22-021350","is_derivative":false,"issuer_cik":"0001765253","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0001765253","owner_cik":null,"owner_name":"Versant Vantage I, L.P.; Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC","owner_display_name":"Versant Vantage I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":750000.0,"shares_display":"750,000","price_per_share":12.2517,"price_display":"12.25","price_state":"stated","total_value":9188775.0,"total_display":"9,188,775.00","total_whole":"9,188,775","shares_owned_after":1464875.0,"shares_owned_after_display":"1,464,875","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-03","filed_date":"2022-06-07","scope":"insider","n_lines":5},{"id":5328599,"accession":"0000899243-21-040777","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-21-040777","line_url":"/filing/0000899243-21-040777","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Vantage I GP-GP, LLC; Versant Side Fund IV, L.P.; Versant Ventures IV, LLC; Versant Vantage I, L.P.; Versant Vantage I GP, L.P.; Versant Ventures VI GP, L.P.; Versant Venture Capital IV, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP-GP, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":550000.0,"shares_display":"550,000","price_per_share":14.837702561454545,"price_display":"14.84","price_state":"stated","total_value":8160736.4088,"total_display":"8,160,736.41","total_whole":"8,160,736","shares_owned_after":1057976.0,"shares_owned_after_display":"1,057,976","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-10-18","filed_date":"2021-10-20","scope":"insider","n_lines":4},{"id":5237384,"accession":"0000899243-21-026766","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-21-026766","line_url":"/filing/0000899243-21-026766#line-3","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Venture Capital VI, L.P.; Versant Ventures VI GP-GP, LLC; Versant Vantage I, L.P.; Versant Ventures VI GP, L.P.","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":157895.0,"shares_display":"157,895","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":3000005.0,"total_display":"3,000,005.00","total_whole":"3,000,005","shares_owned_after":2097938.0,"shares_owned_after_display":"2,097,938","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-28","filed_date":"2021-06-30","scope":"insider"},{"id":2041514,"accession":"0001209191-20-039019","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0001209191-20-039019","line_url":"/filing/0001209191-20-039019","is_derivative":false,"issuer_cik":"0001765253","issuer_name":"Repare Therapeutics Inc.","issuer_ticker":"RPTX","issuer_name_source":null,"issuer_url":"/issuer/0001765253","owner_cik":null,"owner_name":"Versant Vantage I, L.P.; Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC","owner_display_name":"Versant Vantage I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":608282.0,"shares_owned_after_display":"608,282","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-06-23","filed_date":"2020-06-25","scope":"insider","n_lines":2},{"id":2643956,"accession":"0001209191-20-015670","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-015670","line_url":"/filing/0001209191-20-015670#line-4","is_derivative":false,"issuer_cik":"0001619294","issuer_name":"Passage BIO, Inc.","issuer_ticker":"PASG","issuer_name_source":null,"issuer_url":"/issuer/0001619294","owner_cik":null,"owner_name":"Versant Ventures VI GP, L.P.; Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Venture Capital VI, L.P.; Versant Ventures VI GP-GP, LLC; Woiwode Thomas; Versant Vantage I, L.P.","owner_display_name":"Versant Ventures VI GP, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":225000.0,"shares_display":"225,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":4050000.0,"total_display":"4,050,000.00","total_whole":"4,050,000","shares_owned_after":933352.0,"shares_owned_after_display":"933,352","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-03","filed_date":"2020-03-03","scope":"insider"},{"id":8144011,"accession":"0000899243-19-026602","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000899243-19-026602","line_url":"/filing/0000899243-19-026602","is_derivative":false,"issuer_cik":"0001456589","issuer_name":"Oyster Point Pharma, Inc.","issuer_ticker":"OYST","issuer_name_source":null,"issuer_url":"/issuer/0001456589","owner_cik":null,"owner_name":"Versant Ventures IV, LLC; Versant Vantage I, L.P.; Versant Vantage I GP-GP, LLC; Versant Venture Capital VI, L.P.; Versant Ventures VI GP-GP, LLC; Versant Venture Capital IV, L.P.; Versant Ventures VI GP, L.P.; Versant Side Fund IV, L.P.; Versant Vantage I GP, L.P.","owner_display_name":"Versant Ventures IV, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":590000.0,"shares_display":"590,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":9440000.0,"total_display":"9,440,000.00","total_whole":"9,440,000","shares_owned_after":1003658.0,"shares_owned_after_display":"1,003,658","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-04","filed_date":"2019-11-04","scope":"insider","n_lines":3},{"id":7823885,"accession":"0001140361-19-018091","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-19-018091","line_url":"/filing/0001140361-19-018091#line-3","is_derivative":false,"issuer_cik":"0001765253","issuer_name":"Aprea Therapeutics, Inc.","issuer_ticker":"APRE","issuer_name_source":null,"issuer_url":"/issuer/0001765253","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":333333.0,"shares_display":"333,333","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":4999995.0,"total_display":"4,999,995.00","total_whole":"4,999,995","shares_owned_after":333333.0,"shares_owned_after_display":"333,333","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-10-07","filed_date":"2019-10-07","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001840748","name":"LAVA Therapeutics NV","url":"/issuer/0001840748","role":"Ten percent owner","n_filings":2,"first_seen":"2025-09-18","last_seen":"2025-09-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001826457","name":"Monte Rosa Therapeutics, Inc.","url":"/issuer/0001826457","role":"Ten percent owner","n_filings":4,"first_seen":"2021-06-30","last_seen":"2024-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001808158","name":"Repare Therapeutics Inc.","url":"/issuer/0001808158","role":"Ten percent owner","n_filings":2,"first_seen":"2020-06-25","last_seen":"2022-06-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001720725","name":"Oyster Point Pharma, Inc.","url":"/issuer/0001720725","role":"Ten percent owner","n_filings":2,"first_seen":"2019-11-04","last_seen":"2021-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001787297","name":"Passage BIO, Inc.","url":"/issuer/0001787297","role":"Ten percent owner","n_filings":1,"first_seen":"2020-03-03","last_seen":"2020-03-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001781983","name":"Aprea Therapeutics, Inc.","url":"/issuer/0001781983","role":"Ten percent owner","n_filings":1,"first_seen":"2019-10-07","last_seen":"2019-10-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001777653","retrieved_at":"2026-08-23T10:42:38+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}